<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04054882</url>
  </required_header>
  <id_info>
    <org_study_id>sIPV/DTaP-2019-01</org_study_id>
    <nct_id>NCT04054882</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Immunogenicity of Simultaneously Administration of sIPV and DTaP</brief_title>
  <official_title>A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Safety and Immunogenicity of Simultaneously Administration of sIPV and DTaP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Biotec Group Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chengdu Institute of Biological Products Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Institute of Biological Products Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu Province Centers for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Provincial Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sichuan Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes for Food and Drug Control, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China National Biotec Group Company Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects will be recruited and divided into 3 groups:(1)combined immunization of Sabin-IPV
      and DTaP, (2) Sabin-IPV only and (3) DTaP only.

      After finishing the two basic vaccine EPI procedures, the immunogenicity and safety of both
      combined immunization group and individual vaccination groups will be compared and the data
      will be analyzed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is recommended by China Food and Drug Administration (CFDA) that studies on simultaneous
      immunization of Sabin-IPV and DTaP be implemented soon and the immunogenicity and safety
      studies should be conducted. In China according to the current vaccination schedule, the
      arrangement of Sabin-IPV and DTaP falls on the same date -- at infants' 3rd and 4th months of
      age. In order to avoid the vaccination time conflict and explore the feasibility of
      simultaneous immunization, we design this phase 4 clinical trial of simultaneous vaccination
      of the two vaccines.

      To be specific, the subjects were divided into 3 groups. Group 1 : Sabin-IPV (1st, 2nd, and
      3rd doses) and DTaP (1st, 2nd, and 3rd doses) are simultaneously administrated at 3,4,5
      months old ; Group 2 : subjects receive 1 dose of sIPV only at 3,4,5 months old ; Group 3 :
      subjects receive 1 dose of DTaP only at 3,4,5 months old .

      Blood samples would be collected both before vaccination and 28-40 days after the 3rd dose of
      vaccination. Neutralization antibody will be detected to evaluate the seroprotection rates
      and antibody geometric mean concentrations. The safety of both immunization schedules will be
      monitored too.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2019</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion rates at both baseline and 30 days after the 3rd vaccination</measure>
    <time_frame>4 months</time_frame>
    <description>Determine the seroconversion rates of diphtheria, tetanus, pertussis, poliovirus (types I,II,III). Diphtheria titers are determined by toxin neutralization assay; tetanus titers are determined by enzyme-linked immunosorbent assay (ELISA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutralizing antibody titers at both baseline and 30 days after the 3rd vaccination</measure>
    <time_frame>4 months</time_frame>
    <description>Measure neutralizing antibody titers against: (1) poliovirus type I, II and III，(2) anti-pertussis toxoid ,(3) anti- FHA,(4) anti-diphtheria toxoid and (5) anti-tetanic antibodies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>numbers of participants who experience adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>analyse the numbers and rates of participants who have adverse events following immunization</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">702</enrollment>
  <condition>Vaccination</condition>
  <arm_group>
    <arm_group_label>Sabin-IPV and DTaP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>234 subjects are simultaneously administrated with Sabin-IPV and DTaP at the age of 3/4/5 months old, 0.5 ml each dose, respectively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sabin-IPV only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>234 subjects are administrated with Sabin-IPV only at the age of 3/4/5 months old, 0.5 ml each dose, respectively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DTaP only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>234 subjects are administrated with DTaP only at the age of 3/4/5 months old, 0.5 ml each dose, respectively</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sabin-IPV and DTaP</intervention_name>
    <description>simultaneously administration of Sabin-IPV and DTaP</description>
    <arm_group_label>Sabin-IPV and DTaP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sabin-IPV</intervention_name>
    <description>administration of Sabin-IPV only</description>
    <arm_group_label>Sabin-IPV only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP</intervention_name>
    <description>administration of DTaP only</description>
    <arm_group_label>DTaP only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subjects aged 3 months old at the date of recruitment;

          -  with informed consent signed by parent(s) or guardians;

          -  parent(s) or guardians are able to attend all planned clinical appointments and

          -  obey and follow all study instructions;

          -  subjects have not been vaccinated with IPV vaccine, OPV vaccine, DTP vaccine and
             related vaccines;

        Exclusion Criteria:

          -  subject who has a medical history with hypersensitiveness, eclampsia, epilepsy,
             cerebropathy and neurological illness;

          -  allergic to any ingredient of vaccine or with allergy history to any vaccine;

          -  subjects with immunodeficiency or suspected impairment of immunologic function (e.g.
             caused by HIV), or subjects are in the process of immunosuppressor therapy(Taking
             orally injecting of steroid hormone);

          -  administration of immunoglobulins within 30 days prior to this study;

          -  acute febrile disease(temperature ≥ 37.0°C) or infectious disease;

          -  have a clearly diagnosed history of thrombocytopenia or other coagulopathy,

          -  may cause contraindications for subcutaneous injection;

          -  any serious chronic illness, acute infectious diseases, or respiratory diseases;

          -  severe cardiovascular disease, liver and kidney diseases or diabetes mellitus with
             complications;

          -  any kind of infectious, purulent, or allergic skin diseases;

          -  any other factor that makes the investigator determines the subject is unsuitable for
             this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>3 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fenyang Tang</last_name>
    <role>Study Director</role>
    <affiliation>Jiangsu Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fenyang Tang</last_name>
    <phone>+86-25-83759419</phone>
    <email>tfyepi@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaoping Zhu</last_name>
    <phone>+86-852-85596863</phone>
    <email>xiaopingzhu98@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jiangsu Provincial Center for Disease Control and Prevention</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fenyang Tang</last_name>
      <phone>+86-25-83759419</phone>
      <email>tfyepi@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiaoping Zhu</last_name>
      <phone>+86-852-85596863</phone>
      <email>xiaopingzhu98@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 9, 2019</study_first_submitted>
  <study_first_submitted_qc>August 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <last_update_submitted>August 10, 2019</last_update_submitted>
  <last_update_submitted_qc>August 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

